Your browser doesn't support javascript.
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Medicine (Baltimore) ; 95(40): e5077, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27749580


Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown.CASE REPORT: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1.


To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.





Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Pulmonares / Anticorpos Monoclonais / Recidiva Local de Neoplasia / Estadiamento de Neoplasias Tipo de estudo: Relato de casos Aspecto clínico: Prognóstico Limite: Humanos / Masculino / Meia-Idade País/Região como assunto: Ásia Idioma: Inglês Revista: Medicine (Baltimore) Ano de publicação: 2016 Tipo de documento: Artigo País de afiliação: Níger